NCT02018861 2023-09-28A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)Incyte CorporationPhase 1/2 Completed88 enrolled 25 charts